IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding
NCT06870344 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36000
Last updated 2025-08-08
Summary
The purpose of this study is to test different ways to prevent malaria infections after flooding. To accomplish this, the investigators will assign villages to different control strategies and measure the number of malaria infections in each of the villages. Residents of all villages will receive new bed nets, but in some villages, residents will be provided with a monthly medication Dihydroartemisinin-piperaquine (DP) (a drug that is approved by the World Health Organization (WHO) and regulatory authorities and widely used in Africa for Malaria treatment. This drug is not approved by Food and Drug Administration (FDA) because it is not used in the US,) to prevent malaria, while others will also receive a treatment that can be placed into pools of water around the home to prevent mosquitoes from breeding there. The investigators will monitor the participant and their household members for mosquitoes and malaria over a period of 12 months after the flooding This study is important because, similar approaches could be used to prevent malaria after floods, which is occurring more frequently.
Conditions
- Malaria Infection
- Malaria Falciparum
Interventions
- DRUG
-
Dihydroartemisinin piperaquine
Taken orally. 11 kg to less than 17 kg 1 tablet per day for 3 days 40 mg 320 mg 17 kg to less than 25 kg 1½ tablets per day for 3 days 60 mg 480 mg 25 kg to less than 36 kg 2 tablets per day for 3 days 80 mg 640 mg 36 kg to less than 60 kg 3 tablets per day for 3 days 120 mg 960 mg 60 kg to less than 80 kg 4 tablets per day for 3 days 160 mg 1280 mg 80 kg or more 5 tablets per day for 3 days 200 mg 1600 mg For patients weighing less than 11 kg, alternative formulations supplying lower amounts of active substance should be preferred
- COMBINATION_PRODUCT
-
Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis
Study staff will provide adult participant with LLIN(s), DP and with an 8-oz packet of Bti, a pair of latex gloves, a teaspoon, and a tracking form. A staff member will then survey an area (50 m radius) around the house and demonstrate appropriate application in up to 5 potential breeding sites.
- OTHER
-
Long-lasting Insecticidal Net
Distribution of Long-lasting Insecticidal Net to all households on the study.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
North Carolina State University
collaborator OTHER -
Mbarara University of Science and Technology
collaborator OTHER -
University of North Carolina, Chapel Hill
lead OTHER
Principal Investigators
-
Ross Boyce, MD, M.Sc. · University of North Carolina, Chapel Hill
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 0 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-03-12
- Primary Completion
- 2026-07-01
- Completion
- 2026-07-01
Countries
- Uganda
Study Locations
More Related Trials
-
Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi
NCT01326754 ·Status: COMPLETED ·Phase: NA
-
Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission
NCT01575613 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
NCT02389374 ·Status: COMPLETED ·Phase: PHASE4
-
Malaria Therapeutic Efficacy Study, Rwanda
NCT04767217 ·Status: COMPLETED ·Phase: PHASE4
-
Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan
NCT01075945 ·Status: UNKNOWN ·Phase: PHASE4
-
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination
NCT03576313 ·Status: COMPLETED ·Phase: PHASE3
-
Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission
NCT02259426 ·Status: COMPLETED ·Phase: PHASE3
-
The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy
NCT06347471 ·Status: RECRUITING ·Phase: PHASE4
-
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
NCT02836002 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania
NCT03640403 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Efficacy Study of Primaquine and Methylene Blue
NCT02831023 ·Status: COMPLETED ·Phase: PHASE2
-
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
NCT04049916 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon
NCT05340153 ·Status: UNKNOWN ·Phase: PHASE4
-
Emptying Malaria Reservoirs to Accelerate Malaria Elimination in High Transmission Settings
NCT05440773 ·Status: UNKNOWN ·Phase: NA
-
Malaria in Early Life Study
NCT02001428 ·Status: COMPLETED ·Phase: NA
-
Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine
NCT01878357 ·Status: COMPLETED ·Phase: PHASE4
-
Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
NCT04864444 ·Status: COMPLETED ·Phase: NA
-
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
NCT02612545 ·Status: COMPLETED ·Phase: PHASE1
-
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
NCT03454048 ·Status: COMPLETED ·Phase: NA
-
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
NCT02637128 ·Status: COMPLETED ·Phase: PHASE4
-
Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration
NCT02654912 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
NCT00203814 ·Status: COMPLETED ·Phase: NA
-
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
NCT02974348 ·Status: COMPLETED ·Phase: PHASE3
-
ACT for the Home Management in Malagasy Children
NCT00612547 ·Status: COMPLETED
-
Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.
NCT05801198 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2